Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Microbot MedicalMBOT -1.15%29 Cyclically Adjusted PS Ratio is 171.50 as of Aug. 03, 2026, which is 9% below its 10-year median of 187.50. GuruFocus rates MBOT with a GF Score™ of 29/100. The stock has 2 warning signs investors should review. Among 522 Medical Devices & Instruments companies, Microbot Medical ranks worse than 99.81% on this metric.
The historical rank and industry rank for Microbot Medical's Cyclically Adjusted PS Ratio or its related term are showing as below:
MBOT'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 171 Med: 187.5 Max: 259
Current: 214.38
During the past years, Microbot Medical's highest Cyclically Adjusted PS Ratio was 259.00. The lowest was 171.00. And the median was 187.50.
MBOT's Cyclically Adjusted PS Ratio is ranked worse than 99.81% of 522
companies
in the Medical Devices & Instruments industry
Industry Median: 2.26
vs MBOT: 214.38
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Microbot Medical's adjusted revenue per share data for the three months ended in Mar. 2026 was $0.002. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $0.01 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Microbot Medical (NAS:MBOT) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Microbot Medical Cyclically Adjusted PS Ratio Related Terms
Microbot Medical Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for Microbot Medical's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Microbot Medical Cyclically Adjusted PS Ratio Chart
MBOT vs STXS, DXR, KRMD: Cyclically Adjusted PS Ratio Comparison
For the Medical Instruments & Supplies subindustry, Microbot Medical's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Microbot Medical Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Microbot Medical's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Microbot Medical's Cyclically Adjusted PS Ratio falls into.
Microbot Medical Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Microbot Medical's Cyclically Adjusted PS Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 171.50 mean?
Microbot Medical (MBOT) has a Cyclically Adjusted PS Ratio of 171.50 as of Aug. 03, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Microbot Medical and its competitors. This is near median its historical median of 187.50. Over the past decade, Microbot Medical's Cyclically Adjusted PS Ratio has ranged from 171.00 to 259.00. According to the industry distribution chart, Microbot Medical ranks #521 out of 522 companies in the Medical Devices & Instruments industry, placing it in the top 99.8%.
Is Microbot Medical's Cyclically Adjusted PS Ratio too high?
Microbot Medical's current Cyclically Adjusted PS Ratio of 171.50 is near median its 10-year median of 187.50. Over the past 10 years, this metric has ranged from a low of 171.00 to a high of 259.00. The Medical Devices & Instruments industry median Cyclically Adjusted PS Ratio is 2.26. Microbot Medical's value of 171.50 is 7488.5% above this industry median. Based on the distribution chart, Microbot Medical ranks #521 out of 522 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Microbot Medical has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Microbot Medical's Cyclically Adjusted PS Ratio compare to STXS and DXR?
According to the Medical Devices & Instruments industry distribution chart, Microbot Medical ranks #521 out of 522 companies for Cyclically Adjusted PS Ratio. This places Microbot Medical in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 2.26. Microbot Medical's value of 171.50 is 7488.5% above this benchmark. Historically, Microbot Medical's own Cyclically Adjusted PS Ratio has ranged from 171.00 to 259.00 over the past decade. While the company's 10-year median is 187.50 vs. the industry median of 2.26, Microbot Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Medical Devices & Instruments company?
The median Cyclically Adjusted PS Ratio among Medical Devices & Instruments companies is 2.26, based on 522 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Microbot Medical's current Cyclically Adjusted PS Ratio of 171.50 is 7488.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Microbot Medical and its competitors. For the Medical Devices & Instruments industry, the median Cyclically Adjusted PS Ratio is 2.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Microbot Medical's current Cyclically Adjusted PS Ratio is 171.50, which is near median its own 10-year median of 187.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Microbot Medical stock overvalued right now?
Microbot Medical (MBOT) has a current Cyclically Adjusted PS Ratio of 171.50. The current Cyclically Adjusted PS Ratio is 171.50, which is near median its 10-year median of 187.50 and 7488.5% above the Medical Devices & Instruments industry median of 2.26. Microbot Medical's overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Microbot Medical (MBOT), the current Cyclically Adjusted PS Ratio is 171.50 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Microbot Medical Inc is a medical device company specializing in the research, design, and development of next-generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, the company has developed the LIBERTY Endovascular Robotic Surgical System, a fully disposable robot for various endovascular interventional procedures. The company has a single operating and reportable segment, which is the development of robotic devices for endoluminal surgery.
29GF Score
Get the complete analysis for MBOT
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MBOT has been successfully added to your 
